EGFR and non-small cell lung carcinoma: A case report on a patient with advanced NSCLC carrying the I740_K745dup mutation revealed that treatment with a first-generation EGFR-TKI achieved 4 months of PFS in the first line, while second-line treatment with afatinib extended the PFS up to 13.4 months, revealing that for individuals with such a mutation, afatinib would be a superior therapy option [24].